+91-98 455 710 46 | info@nckpharma.com

Pharma News

Keep updating your pharma knowledge
25 Apr 2015

FDA approves first generic Copaxone to treat multiple sclerosis

The U.S. Food and Drug Administration today approved the first generic version of Copaxone (glatiramer acetate injection), used to treat patients with relapsing forms of multiple sclerosis (MS).

Sandoz has received FDA approval to market generic glatiramer acetate in a 20 mg/1 ml daily injection.

Glatiramer acetate (also known as Copolymer 1, Cop-1, or Copaxone – as marketed by Teva Pharmaceuticals) is an immunomodulator drug currently used to treat multiple sclerosis.

Glatiramer acetate has been approved for marketing in 49 countries worldwide, including the United States, Israel, Canada and 24 European Union Countries.

Leave a Reply


The reCAPTCHA verification period has expired. Please reload the page.

Upskill Your Pharma Knowledge

Explore Next Gen Learning

Case Studies & Caselets | Simulation Based Learning | E-Lectures | Online Self Competency Assessments

Thank You for Subscription!